Exploring the conformational dynamics and thermodynamics of EGFR S768I and G719X+S768I mutations in non-small cell lung cancer: An in silico approaches

被引:1
|
作者
Wang, Jun-Ling [2 ]
Liu, Ming-Sheng [3 ]
Fu, Yu-Dong [4 ]
Kan, Qiang-Bo [4 ]
Li, Chun-Yan [5 ]
Ma, Rong [2 ]
Fang, Zhe-Wei [2 ]
Liu, Hong-Xia [2 ]
Li, Meng-Xian [2 ]
Lv, Jia-Ling [5 ]
Sang, Peng [6 ]
Zhang, Chao [1 ]
Li, Hong-Wei [1 ]
机构
[1] Kunming Med Univ, Affiliated Qujing Hosp, Dept Oncol, Yuanlin Rd 1, Qujing 655000, Peoples R China
[2] Kunming Med Univ, Affiliated Qujing Hosp, Clin Lab, Qujing 655000, Peoples R China
[3] Kunming Med Univ, Affiliated Qujing Hosp, Dept Urol Surg, Qujing 655000, Peoples R China
[4] Kunming Med Univ, Affiliated Qujing Hosp, Dept Thorac Surg, Qujing 655000, Peoples R China
[5] Kunming Med Univ, Affiliated Qujing Hosp, Dept Oncol, Qujing 655000, Peoples R China
[6] Dali Univ, Sch Life Sci, Dali 671003, Peoples R China
来源
OPEN LIFE SCIENCES | 2023年 / 18卷 / 01期
关键词
epidermal growth factor receptor G719X and S768I mutations; non-small cell lung cancer; molecular dynamics simulation; conformation; free energy landscape; MOLECULAR-DYNAMICS;
D O I
10.1515/biol-2022-0768
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Non-small cell lung cancer (NSCLC) is often driven by mutations in the epidermal growth factor receptor (EGFR) gene. However, rare mutations such as G719X and S768I lack standard anti-EGFR targeted therapies. Understanding the structural differences between wild-type EGFR and these rare mutants is crucial for developing EGFR-targeted drugs. We performed a systematic analysis using molecular dynamics simulations, essential dynamics (ED), molecular mechanics Poisson-Boltzmann surface area, and free energy calculation methods to compare the kinetic properties, molecular motion, and free energy distribution between wild-type EGFR and the rare mutants' structures G719X-EGFR, S768I-EGFR, and G719X + S768I-EGFR. Our results showed that S768I-EGFR and G719X + S768I-EGFR have higher global and local conformational flexibility and lower thermal and global structural stability than WT-EGFR. ED analysis revealed different molecular motion patterns between S768I-EGFR, G719X + S768I-EGFR, and WT-EGFR. The A-loop and alpha C-helix, crucial structural elements related to the active state, showed a tendency toward active state development, providing a molecular mechanism explanation for NSCLC caused by EGFR S768I and EGFR G719C + S768I mutations. The present study may be helpful in the development of new EGFR-targeted drugs based on the structure of rare mutations. Our findings may aid in developing new targeted treatments for patients with EGFR S768I and EGFR G719X + S768I mutations.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer
    Ishimoto, Osamu
    Ishida, Takashi
    Honda, Yoshihiro
    Munakata, Mitsuru
    Sugawara, Shunichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (01) : 43 - 47
  • [32] A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer
    Yoshikazu Hasegawa
    Isamu Okamoto
    Ken Takezawa
    Masaaki Miyazaki
    Junji Tsurutani
    Kimio Yonesaka
    Ryotaroh Morinaga
    Asuka Tsuya
    Masaaki Terashima
    Toshihiro Kudoh
    Koichi Azuma
    Takayasu Kurata
    Tatsuyuki Nishikawa
    Masahiro Fukuoka
    Yasumasa Nishimura
    Kazuhiko Nakagawa
    Investigational New Drugs, 2013, 31 : 599 - 604
  • [33] A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer
    Hasegawa, Yoshikazu
    Okamoto, Isamu
    Takezawa, Ken
    Miyazaki, Masaaki
    Tsurutani, Junji
    Yonesaka, Kimio
    Morinaga, Ryotaroh
    Tsuya, Asuka
    Terashima, Masaaki
    Kudoh, Toshihiro
    Azuma, Koichi
    Kurata, Takayasu
    Nishikawa, Tatsuyuki
    Fukuoka, Masahiro
    Nishimura, Yasumasa
    Nakagawa, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (03) : 599 - 604
  • [34] A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients
    Satoshi Yoda
    Kenzo Soejima
    Hiroyuki Yasuda
    Katsuhiko Naoki
    Ichiro Kawada
    Hideo Watanabe
    Ichiro Nakachi
    Ryosuke Satomi
    Sohei Nakayama
    Sinnosuke Ikemura
    Hideki Terai
    Takashi Sato
    Maiko Morosawa
    Koichiro Asano
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 717 - 722
  • [35] A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer
    Takigawa, Nagio
    Kiura, Katsuyuki
    Hotta, Katsuyuki
    Hosokawa, Shinobu
    Nogami, Naoyuki
    Aoe, Keisuke
    Gemba, Kenichi
    Fujiwara, Keiichi
    Harita, Shingo
    Takemoto, Mitsuhiro
    Himei, Kengo
    Shinkai, Tetsu
    Fujiwara, Yoshirou
    Takata, Saburo
    Tabata, Masahiro
    Kanazawa, Susumu
    Tanimoto, Mitsune
    LUNG CANCER, 2011, 71 (01) : 60 - 64
  • [36] Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer
    Takiguchi, Yuichi
    Tada, Yuji
    Gemma, Akihiko
    Kudoh, Shoji
    Hino, Mitsunori
    Yoshimori, Kozo
    Yoshimura, Akinobu
    Nagao, Keiichi
    Niitani, Hisanobu
    LUNG CANCER, 2010, 68 (03) : 409 - 414
  • [37] A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients
    Yoda, Satoshi
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Naoki, Katsuhiko
    Kawada, Ichiro
    Watanabe, Hideo
    Nakachi, Ichiro
    Satomi, Ryosuke
    Nakayama, Sohei
    Ikemura, Sinnosuke
    Terai, Hideki
    Sato, Takashi
    Morosawa, Maiko
    Asano, Koichiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (03) : 717 - 722
  • [38] Overcoming resistance by ALK compound mutation (I1171S+G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer
    Takahashi, Ken
    Seto, Yosuke
    Okada, Koutaroh
    Uematsu, Shinya
    Uchibori, Ken
    Tsukahara, Mika
    Oh-hara, Tomoko
    Fujita, Naoya
    Yanagitani, Noriko
    Nishio, Makoto
    Okubo, Kenichi
    Katayama, Ryohei
    THORACIC CANCER, 2020, 11 (03) : 581 - 587
  • [39] A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer
    Chikamori, Kenichi
    Kishino, Daizo
    Takigawa, Nagio
    Hotta, Katsuyuki
    Nogami, Naoyuki
    Kamei, Haruhito
    Kuyama, Shoichi
    Gemba, Kenichi
    Takemoto, Mitsuhiro
    Kanazawa, Susumu
    Ueoka, Hiroshi
    Segawa, Yoshihiko
    Takata, Saburo
    Tabata, Masahiro
    Kiura, Katsuyuki
    Tanimoto, Mitsune
    LUNG CANCER, 2009, 65 (01) : 74 - 79
  • [40] Phase I/II Study of Docetaxel and S-1 in Previously-Treated Patients with Advanced Non-Small Cell Lung Cancer: LOGIK0408
    Takayama, Koichi
    Uchino, Junji
    Fujita, Masaki
    Tokunaga, Shoji
    Imanaga, Tomotoshi
    Morinaga, Ryotaro
    Ebi, Noriyuki
    Saeki, Sho
    Matsukizono, Kazuya
    Wataya, Hiroshi
    Yamada, Tadaaki
    Nakanishi, Yoichi
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (12)